JAK1 and Alzheimer disease: Interestingly, approval of oclacitinib (selective JAK1) for AD in dogs [18] occurred as early as 2013, followed by approvals of baricitinib (JAK1/JAK2) and upadacitinib (JAK1) for rheumatologic indications.